CRMD
CorMedix Inc.
Biotechnology
Market Cap$621M
5Y Perf.+79.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CRMD vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-54.6%
CRMD vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CRMD | ACAD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $621M | $3.86B |
| Revenue (TTM) | $312M | $1.10B |
| Net Income (TTM) | $163M | $376M |
| Gross Margin | 88.5% | 91.5% |
| Operating Margin | 48.2% | 7.4% |
| Forward P/E | 14.2x | 50.9x |
| Total Debt | $149M | $52M |
| Cash & Equiv. | $146M | $178M |
CRMD vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CRMD
ACAD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| CorMedix Inc. (CRMD) | 100 | 179.2 | +79.2% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.4 | -54.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRMD vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRMD leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. ACADIA Pharmaceuticals Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CRMD
CorMedix Inc.
The Growth Play
CRMD carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 6.2%, EPS growth 7.8%, 3Y rev CAGR 15.8%
- 6.2% revenue growth vs ACAD's 11.9%
- Lower P/E (14.2x vs 50.9x)
Best for: growth exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.26
- -22.9% 10Y total return vs CRMD's -51.4%
- Lower volatility, beta 1.26, Low D/E 4.3%, current ratio 3.83x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRMD | 6.2% revenue growth vs ACAD's 11.9% |
| Value | CRMD | Lower P/E (14.2x vs 50.9x) |
| Quality / Margins | CRMD | 52.3% margin vs ACAD's 34.3% |
| Stability / Safety | ACAD | Beta 1.26 vs CRMD's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACAD | +52.4% vs CRMD's -32.2% |
| Efficiency (ROA) | CRMD | 33.0% ROA vs ACAD's 26.2%, ROIC 49.7% vs 10.0% |
CRMD vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2018
CRMD vs ACAD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRMDLAGGINGACAD
ACADACADIA Pharmaceutical…
2leads
CRMDCorMedix Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ACADMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRMD5/6
Valuation MetricsMultiples, price ratios, and targets
CRMD6/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
ACAD4/6
Risk & VolatilityBeta, volatility, and downside exposure
ACAD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRMD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD is the larger business by revenue, generating $1.1B annually — 3.5x CRMD's $312M. CRMD is the more profitable business, keeping 52.3% of every revenue dollar as net income compared to ACAD's 34.3%. On growth, CRMD holds the edge at +3.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CRMDCorMedix Inc. | ACADACADIA Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $312M | $1.1B |
| EBITDAEarnings before interest/tax | $165M | $96M |
| Net IncomeAfter-tax profit | $163M | $376M |
| Free Cash FlowCash after capex | $174M | $212M |
| Gross MarginGross profit ÷ Revenue | +88.5% | +91.5% |
| Operating MarginEBIT ÷ Revenue | +48.2% | +7.4% |
| Net MarginNet income ÷ Revenue | +52.3% | +34.3% |
| FCF MarginFCF ÷ Revenue | +56.0% | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.1% | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -31.8% | -81.8% |
CRMD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
CRMD leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 3.9x trailing earnings, CRMD trades at a 61% valuation discount to ACAD's 9.9x P/E. On an enterprise value basis, CRMD's 3.8x EV/EBITDA is more attractive than ACAD's 26.9x.
| Metric | CRMDCorMedix Inc. | ACADACADIA Pharmaceut… |
|---|---|---|
| Market CapShares × price | $621M | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $624M | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | 3.88x | 9.85x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.18x | 50.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 3.78x | 26.91x |
| Price / SalesMarket cap ÷ Revenue | 1.99x | 3.61x |
| Price / BookPrice ÷ Book value/share | 1.57x | 3.15x |
| Price / FCFMarket cap ÷ FCF | 3.60x | 36.74x |
CRMD leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — CRMD and ACAD each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
CRMD delivers a 58.5% return on equity — every $100 of shareholder capital generates $58 in annual profit, vs $36 for ACAD. ACAD carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRMD's 0.37x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs CRMD's 5/9, reflecting solid financial health.
| Metric | CRMDCorMedix Inc. | ACADACADIA Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +58.5% | +35.6% |
| ROA (TTM)Return on assets | +33.0% | +26.2% |
| ROICReturn on invested capital | +49.7% | +10.0% |
| ROCEReturn on capital employed | +40.8% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.37x | 0.04x |
| Net DebtTotal debt minus cash | $3M | -$126M |
| Cash & Equiv.Liquid assets | $146M | $178M |
| Total DebtShort + long-term debt | $149M | $52M |
| Interest CoverageEBIT ÷ Interest expense | 53.97x | — |
Evenly matched — CRMD and ACAD each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ACAD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,710 today (with dividends reinvested), compared to $9,307 for CRMD. Over the past 12 months, ACAD leads with a +52.4% total return vs CRMD's -32.2%. The 3-year compound annual growth rate (CAGR) favors CRMD at 14.7% vs ACAD's 1.5% — a key indicator of consistent wealth creation.
| Metric | CRMDCorMedix Inc. | ACADACADIA Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -34.9% | -13.7% |
| 1-Year ReturnPast 12 months | -32.2% | +52.4% |
| 3-Year ReturnCumulative with dividends | +50.9% | +4.7% |
| 5-Year ReturnCumulative with dividends | -6.9% | +7.1% |
| 10-Year ReturnCumulative with dividends | -51.4% | -22.9% |
| CAGR (3Y)Annualised 3-year return | +14.7% | +1.5% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
ACAD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than CRMD's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACAD currently trades 81.1% from its 52-week high vs CRMD's 45.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CRMDCorMedix Inc. | ACADACADIA Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.26x |
| 52-Week HighHighest price in past year | $17.43 | $27.81 |
| 52-Week LowLowest price in past year | $6.13 | $14.45 |
| % of 52W HighCurrent price vs 52-week peak | +45.4% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 64.7 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 1.8M |
ACAD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CRMD as "Buy" and ACAD as "Buy". Consensus price targets imply 76.8% upside for CRMD (target: $14) vs 54.1% for ACAD (target: $35).
| Metric | CRMDCorMedix Inc. | ACADACADIA Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $14.00 | $34.78 |
| # AnalystsCovering analysts | 8 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRMD leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). ACAD leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallCorMedix Inc. (CRMD)Leads 2 of 6 categories
Loading custom metrics...
CRMD vs ACAD: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CRMD or ACAD a better buy right now?
For growth investors, CorMedix Inc.
(CRMD) is the stronger pick with 617. 0% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). CorMedix Inc. (CRMD) offers the better valuation at 3. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate CorMedix Inc. (CRMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CRMD or ACAD?
On trailing P/E, CorMedix Inc.
(CRMD) is the cheapest at 3. 9x versus ACADIA Pharmaceuticals Inc. at 9. 9x. On forward P/E, CorMedix Inc. is actually cheaper at 14. 2x.
03Which is the better long-term investment — CRMD or ACAD?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +7. 1%, compared to -6. 9% for CorMedix Inc. (CRMD). Over 10 years, the gap is even starker: ACAD returned -22. 9% versus CRMD's -51. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CRMD or ACAD?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 26β versus CorMedix Inc. 's 1. 26β — meaning CRMD is approximately 0% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 37% for CorMedix Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CRMD or ACAD?
By revenue growth (latest reported year), CorMedix Inc.
(CRMD) is pulling ahead at 617. 0% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: CorMedix Inc. grew EPS 780. 0% year-over-year, compared to 68. 4% for ACADIA Pharmaceuticals Inc.. Over a 3-year CAGR, CRMD leads at 1583% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CRMD or ACAD?
CorMedix Inc.
(CRMD) is the more profitable company, earning 52. 3% net margin versus 36. 5% for ACADIA Pharmaceuticals Inc. — meaning it keeps 52. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRMD leads at 48. 2% versus 9. 8% for ACAD. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CRMD or ACAD more undervalued right now?
On forward earnings alone, CorMedix Inc.
(CRMD) trades at 14. 2x forward P/E versus 50. 9x for ACADIA Pharmaceuticals Inc. — 36. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRMD: 76. 8% to $14. 00.
08Which pays a better dividend — CRMD or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CRMD or ACAD better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (ACAD: -22. 9%, CRMD: -51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CRMD and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CRMD is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CRMD: 312.1% · ACAD: 9.7%)Net Margin>
%
(CRMD: 52.3% · ACAD: 34.3%)P/E Ratio<
x
(CRMD: 3.9x · ACAD: 9.9x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.